|
WO2021055985A1
|
|
Ipsc-derived, hypoimmunogenic, myeloid progenitor cells
|
|
WO2018071910A2
|
|
Anti-il1-rap antibodies
|
|
AU2017343565A1
|
|
Isoquinolidinobenzodiazepine (IQB)-1(chloromethyl)-2,3-dihydro-1H-benzo[e]indole (CBI) dimers
|
|
WO2018053552A2
|
|
Isoquinolidinobenzodiazepines
|
|
KR20180085002A
|
|
Humanized anti-CLL-1 antibody
|
|
US2018312592A1
|
|
Cysteine-substituted immunoglobulins
|
|
WO2016179319A1
|
|
Chimeric antigen receptors with ctla4 signal transduction domains
|
|
US2016271142A1
|
|
Isoquinolidinobenzodiazepines
|
|
WO2014100772A1
|
|
Antibodies that bind membrane-bound il1rap
|
|
US2013295118A1
|
|
Antibodies specific for CLL-1
|
|
EP2729560A1
|
|
Megakaryocyte progenitor cells for production of platelets
|
|
WO2013006490A2
|
|
Antibodies that specifically bind to tim3
|
|
WO2009120905A2
|
|
Immunoglobulin and/or toll-like receptor proteins associated with myelogenous haematological proliferative disorders and uses thereof
|
|
WO2008070861A2
|
|
Methods and compositions for treating systemic lupus erythematosus
|
|
WO2007130923A2
|
|
Portable platform cytometric system with isolation chamber
|
|
AU2007214468A1
|
|
Methods and compositions for enhancing engraftment of hematopoietic stem cells
|
|
US2008003224A1
|
|
Compositions and methods for treating haematological proliferative disorders
|
|
AU2005299379A1
|
|
Methods of expanding myeloid cell populations and uses thereof
|
